source
- Sanofi weighs $40 billion Insmed acquisition, seen as strategic fit in respiratory marketAnalysts are reporting that Sanofi is considering buying Insmed, a biotech focused on respiratory therapies. The potential transaction could be valued at up to $40 billion, making it one of the lar…
- FDA delays decision on Savara's rare lung disease therapy, pushing back deadlineThe FDA announced it will not meet the Nov. 22 PDUFA date for Savara's biologics license application for its inhaled therapy molgramostim (Molbreevi) targeting autoimmune pulmonary alveolar protein…